文献速递生殖医学妇科

BRCA突变携带者及其伴侣对生殖选择的认知与态度

Awareness and attitude regarding reproductive options of persons carrying a BRCA mutation and their partners.
PubMed 文献 · Hum Reprod · 2017-01-01

荷兰一项横断面调查纳入191名BRCA突变携带者及其伴侣,评估其对胚胎植入前遗传学诊断(PGD)和产前诊断(PND)的认知与态度。66%知晓PGD、61%知晓PND,80%接受PGD、26%接受PND;39%会考虑使用PGD、20%会考虑使用PND。教育程度高与知晓相关,癌症史和感知严重性高与考虑使用相关。

要点

  • BRCA突变携带者及伴侣中66%知晓PGD、61%知晓PND,80%接受PGD、26%接受PND。
  • 仅39%会考虑使用PGD、20%会考虑使用PND,知晓与接受度较高但个人使用意愿较低。
  • 教育程度高者更知晓PGD和PND(均P<0.001),癌症史和感知严重性高者更考虑使用。

核心结论

  • BRCA突变携带者及其伴侣对PGD和PND的知晓率相对较高(66%和61%),对PGD接受度为80%、对PND接受度为26%。
  • 仍需改善信息提供,以及时告知所有遗传性乳腺癌卵巢癌(HBOC)夫妇可用的生殖选择,使其做出平衡的生殖决策。

研究设计与样本

  • 横断面调查,2012年7月至2013年6月完成,共191名参与者。
  • 参与者通过患者组织(88%)和荷兰两个临床遗传学部门的数据库(12%)招募。
  • 男性和女性BRCA携带者及其伴侣完成在线调查,评估人口学和医学特征以及PGD和PND的知晓、知识、接受度和考虑使用情况。

主要发现

  • 受访者多数为女性(87%)、处于生育年龄(86%),约半数报告未来有生育意愿。
  • 66%知晓PGD、61%知晓PND;PGD知识得分为5.5分(9分制);PGD接受度80%、PND接受度26%。
  • 少数人会个人考虑使用PGD(39%)或PND(20%)。
  • 教育程度较高者更可能知晓PGD(P<0.001)和PND(P<0.001);生育意愿更迫切者更常知晓PGD(P=0.044)且PGD知识更多(P=0.001)。
  • PGD接受度与PGD知识正相关(P=0.047);伴侣的PND接受度高于携带者(P=0.001)。

临床怎么用

  • 作者认为仍需改善信息提供,以及时告知所有HBOC夫妇可用的生殖选择,使其做出平衡的生殖决策。
  • 作者认为这可能减少因决策冲突和可能的后悔带来的负面心理影响风险。

局限性

  • 临床遗传学部门邀请的参与者应答率(23%)低,可能与同一目标群体中同时进行的类似招募策略研究有关,可能导致选择偏倚。
  • PGD知识测量工具尚未验证,因为目前文献中尚无此类工具。
  • 横断面设计限制因果结论的得出。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: To what extent are BRCA mutation carriers and their partners in the Netherlands aware about preimplantation genetic diagnosis (PGD) and prenatal diagnosis (PND) as reproductive options and what is their attitude towards these options? SUMMARY ANSWER: Awareness of PGD (66%) and PND (61%) among BRCA mutation carriers and their partners is relatively high and 80% and 26%, respectively, of BRCA carriers and their partners find offering PGD and PND for hereditary breast and ovarian cancer (HBOC) acceptable. WHAT IS KNOWN ALREADY: Internationally, awareness of PGD among persons with a genetic cancer predisposition appears to be relatively low (35%) and although acceptability is generally high (71%), only a small proportion of mutation carriers would consider using PGD (36%). However, for HBOC, there are no studies available that investigated the perspective of individuals with a confirmed BRCA1/2 mutation and their partners about PGD and PND including demographic and medical correlates of awareness and acceptability. STUDY DESIGN, SIZE, DURATION: A cross-sectional survey was completed by 191 participants between July 2012 and June 2013. Participants were recruited through patient organizations (88%) and the databases of two Clinical Genetics departments in the Netherlands (12%). PARTICIPANTS/MATERIALS, SETTING, METHODS: Male and female BRCA carriers and their partners completed an online survey, which assessed demographic and medical characteristics, and awareness, knowledge, acceptability and consideration of PGD and PND as main outcomes. Correlations between demographic and medical characteristics and the main outcomes were investigated. MAIN RESULTS AND ROLE OF CHANCE: The majority of respondents were female (87%), of reproductive age (86%) and about half reported a desire for a child in the future. About two-thirds (66%) were aware of PGD and 61% of PND for HBOC. PGD knowledge was moderate (5.5 on a 9-point scale) and acceptability of PGD and PND for HBOC was 80% and 26%, respectively. A minority would personally consider using PGD (39%) or PND (20%). Individuals with a higher educational level were more likely to be aware of PGD (P < 0.001) and PND (P < 0.001) and persons with a more immediate child wish were more often aware of PGD (P = 0.044) and had more knowledge about PGD (P = 0.001). PGD acceptability was positively associated with knowledge about PGD (P = 0.047), and PND acceptability was higher among partners in comparison to carriers (P = 0.001). Participants with a history of cancer and with a higher perceived seriousness of breast and ovarian cancer were more likely to consider using PGD (P = 0.003 and P < 0.001 respectively) or PND (P = 0.021 and P = 0.017 respectively). LIMITATIONS, REASONS FOR CAUTION: The response rate (23%) of participants invited by the clinical genetics departments was low, probably related to a simultaneous study that used a similar recruitment strategy within the same target group, which may have resulted in selection bias. Moreover, PGD knowledge was measured with an instrument that is not yet validated since to date such an instrument is not available in the literature. Finally, the cross-sectional design of this study limits us from drawing any causal conclusions. WIDER IMPLICATIONS OF THE FINDINGS: Improvement of information provision remains needed, in order to timely inform all couples with HBOC about the available reproductive options and enable them to make a balanced reproductive decision. This may limit the risk of negative psychological impact due to decisional conflict and possible regret. STUDY FUNDING/COMPETING INTEREST(S): The Dutch breast cancer foundation Stichting Pink Ribbon (grant number 2010.PS11.C74). None of the authors have competing interests to declare. TRIAL REGISTRATION NUMBER: Not applicable.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Gietel-Habets JJ, de Die-Smulders CE, Derks-Smeets IA, et al. Awareness and attitude regarding reproductive options of persons carrying a BRCA mutation and their partners. Hum Reprod. 2017. PMID: 28073972. doi:10.1093/humrep/dew352

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。